Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-C11: Pembrolizumab Plus Chemotherapy in Newly Diagnosed Classical Hodgkin Lymphoma
2022-501615-14-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co. Primary endpoint: Complete Response at End of Study Intervention (Independent Central Review). Started Aug 2023; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-501615-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501615-14-00.